Asia Pacific Embolotherapy Market

The embolotherapy market in Asia Pacific is expected to grow from US$ 781.80 million in 2022 to US$ 1,272.58 million by 2028. It is estimated to grow at a CAGR of 8.5% from 2022 to 2028. 

Growing Use of Liquid Embolic Agents to Fuel Embolotherapy Market in Asia Pacific during 2022–2028 

Liquid embolic agents are gaining attention owing to their advantages in distal infiltration where solid embolic agents cannot reach, enabling extensive embolization. Liquid formulations have a well-established role in the therapeutic embolization of blood vessels with the widespread use of cyanoacrylate glues, precipitating polymer suspensions, sclerosing agents, and viscous emulsions of oil and chemotherapeutic agents—the emerging market for next-generation liquid embolic aims to address a few shortcomings of the currently used products. There are currently two main liquid agents used for embolization procedures in the clinics—ethylene-vinyl alcohol (EVA) copolymer solution (such as Onyx and Medtronic) and iodinated poppy seed oil (such as Lipiodol and Guerbet). Lipiodol has been used for many years as an imaging agent and is used off-label in the treatment of hepatocellular carcinoma (HCC), where it is mixed with aqueous chemotherapy solutions to create a viscous emulsion that aids in temporarily reducing blood flow. Prominent players are constantly focusing on maintaining their leadership position in the market by continuously introducing new products and improving the existing products to broaden the use of embolotherapy techniques. For instance, in July 2021, Terumo Medical Corporation announced the launch of its AZUR Vascular Plug. The company claims that the plug is compatible with a microcatheter to occlude arteries up to 8mm in diameter. The newest addition to Terumo's robust embolization portfolio is indicated for use to reduce or block the rate of blood flow in arteries of the peripheral vasculature. In March 2022, Guerbet announced that it would double its line of microcatheters and launch a new line of guidewires to offer a broad range of interventional imaging and embolization solutions. SeQure by Guerbet is the reflux control microcatheter enabling a fluid barrier technology for flow-directed embolization. The new model is designed to deliver targeted treatment and use a wider range of beads blocks, from extra-small to large. Therefore, the use of liquid embolic is likely to introduce new trends in the embolotherapy market. 

Market Overview 

The Asia Pacific embolotherapy market is segmented into China, Japan, India, Australia, South Korea, and the rest of Asia Pacific. The growth of the market in Asia Pacific is attributed to factors such as the rising prevalence of brain stroke, coronary artery diseases, and heart diseases; increasing surgical procedures; growing number of hospitals and ambulatory surgeries centers; focus by industry players in Japan; and developing healthcare infrastructure in India. China faces a high burden of cardiovascular diseases due to smoking and unhealthy diet. As per the World Heart Federation, 87% of total adult deaths in China are recorded due to noncommunicable diseases, including CVDs. The incidence of stroke and abdominal aortic aneurysms has increased in the past years, which is driving the adoption of embolotherapy. According to the Global Burden of Disease Study 2019, there were 3.94 million new stroke cases, 28.76 million prevalent cases, and 2.19 million deaths due to stroke in China. 

Asia Pacific Embolotherapy Market Revenue and Forecast to 2028 (US$ Million) 

Asia Pacific Embolotherapy Strategic Insights

Strategic insights for the Asia Pacific Embolotherapy provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Embolotherapy Report Scope

Asia Pacific Embolotherapy Regional Insights

The geographic scope of the Asia Pacific Embolotherapy refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Asia Pacific Embolotherapy Market Segmentation 

The Asia Pacific embolotherapy market is segmented into product, disease indication, procedure, end user, and country. 
Based on product, the market is segmented into embolic agents and support devices. The embolic agents segment registered the largest market share in 2022. Based on disease indication, the market is categorized into cancer, neurological diseases, urological and nephrological disorders, peripheral vascular diseases, gastrointestinal disorders, and others. The cancer segment held the largest market share in 2022. Based on procedure, the Asia Pacific embolotherapy market is segmented into transcatheter arterial embolization (TAE), transcatheter arterial radioembolization/selective internal radiation therapy, and transarterial chemoembolization (TACE). The transcatheter arterial embolization (TAE) segment held the largest market share in 2022. Based on end user, the Asia Pacific embolotherapy market is segmented into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment held the largest market share in 2022. Based on country, the market is segmented into China, Japan, India, Australia, South Korea, and Rest of Asia Pacific. China dominated the market share in 2022. Abbott Laboratories; Boston Scientific Corporation; Cook Medical LLC; Johnson & Johnson; Medtronic; Acandis GmbH; Balt USA LLC; Stryker Corporation; Guerbet LLC; and Terumo Corporation are the leading companies operating in the embolotherapy market in the region.